Trade

with

Achillion Pharmaceuticals Inc
(NASDAQ: ACHN)
AdChoices
10.99
+0.02
+0.18%
After Hours :
11.00
+0.01
+0.09%

Open

10.98

Previous Close

10.97

Volume (Avg)

3.54M (5.93M)

Day's Range

10.76-11.35

52Wk Range

2.26-13.80

Market Cap.

1.07B

Dividend Rate ( Yield )

-

Beta

2.33

Shares Outstanding

97.79M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -58.95M

    • Market Cap.

    • 1.07B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.33

    • Forward P/E

    • -13.30

    • Price/Sales

    • -

    • Price/Book Value

    • 8.52

    • Price/Cash flow

    • -19.53

      • EBITDA

      • -58.50M

      • Return on Capital %

      • -36.19

      • Return on Equity %

      • -38.97

      • Return on Assets %

      • -36.19

      • Book Value/Share

      • 1.29

      • Shares Outstanding

      • 97.79M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 18.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.69

        • Cashflow Estimate

        • -1.31

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 14.51

              • 2.92

              • Quick Ratio

              • 14.30

              • 2.35

              • Interest Coverage

              • -1,593.97

              • 38.02

              • Leverage Ratio

              • 1.07

              • 2.21

              • Book Value/Share

              • 1.29

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -17.99

                • 188.68

                • P/E Ratio 5-Year High

                • -22.64

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.41

                • 124.82

                • Price/Sales Ratio

                • -

                • 8.72

                • Price/Book Value

                • 8.52

                • 7.95

                • Price/Cash Flow Ratio

                • -19.53

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -38.97

                    (-97.80)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -36.19

                    (-68.90)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -38.86

                    (-86.10)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -59.48M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -19.53
                  Ownership

                  Institutional Ownership

                  86.80%

                  Top 10 Institutions

                  54.39%

                  Mutual Fund Ownership

                  37.36%

                  Float

                  58.23%

                  5% / Insider Ownership

                  0.24%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    5,539,400

                  • 0.00

                  • 5.66

                  • VA CollegeAmerica Small Cap World

                  •  

                    4,930,000

                  • 19.37

                  • 5.04

                  • Bb Biotech AG

                  •  

                    1,779,340

                  • 0.00

                  • 1.81

                  • Goldman Sachs Small/Mid Cap Growth Fund

                  •  

                    1,543,122

                  • -9.57

                  • 1.58

                  • iShares Russell 2000 (AU)

                  •  

                    1,512,913

                  • -1.01

                  • 1.70

                  • Vanguard Small Cap Index

                  •  

                    1,446,132

                  • 0.80

                  • 1.48

                  • SPDR® S&P Biotech ETF

                  •  

                    1,403,237

                  • 0.60

                  • 1.58

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,350,468

                  • 0.00

                  • 1.38

                  • iShares Nasdaq Biotechnology

                  •  

                    1,307,189

                  • 3.08

                  • 1.47

                  • Pictet-Biotech

                  •  

                    1,220,502

                  • 0.07

                  • 3.03

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • RA Capital Management, LLC

                  •  

                    11,032,014

                  • -37.69%

                  • 11.28

                  • Fidelity Management and Research Company

                  •  

                    6,563,772

                  • +641.50%

                  • 6.71

                  • Qvt Financial LP

                  •  

                    5,109,153

                  • -53.42%

                  • 5.22

                  • Vanguard Group, Inc.

                  •  

                    4,889,994

                  • -4.47%

                  • 5.00

                  • Domain Partners VIII, LP

                  •  

                    4,572,968

                  • -20.79%

                  • 4.68

                  • Capital World Investors

                  •  

                    4,130,000

                  • 0.00%

                  • 4.22

                  • BlackRock Fund Advisors

                  •  

                    3,551,912

                  • -1.88%

                  • 3.63

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Achillion Pharmaceuticals Inc was incorporated on August 17, 1998 in Delaware. The Company is a biopharmaceutical company which focuses on the discoveries, develops and commercializes treatments for infectious diseases. Within the an...moreti-infective market, it is currently focusing its efforts on developing commercially competitive, short-duration combination therapies for the treatment of chronic hepatitis C infection that are administered once-daily, orally, and without ribavirin. The Company competes with Abbvie, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Enanta, Gilead, GlaxoSmithKline, Idenix, Johnson & Johnson, Presidio, Medivir, Merck, Novartis, Pfizer, Roche, Valeant and Vertex. The Company's drug candidates is subject to extensive governmental regulations relating to, among other...more things, research, testing, development, manufacturing, safety, efficacy, record keeping, labeling, marketing and distribution of drugs.lessless

                  Key People

                  Milind S. Deshpande,PhD

                  CEO/President/Director

                  Mr. David I. Scheer

                  Chairman of the Board/Director

                  Mary Kay Fenton

                  CFO/Chief Accounting Officer/Executive VP/Secretary

                  Gautam Shah,PhD

                  Executive VP/Other Executive Officer

                  Joseph Truitt

                  Executive VP/Other Executive Officer

                  • Achillion Pharmaceuticals Inc

                  • 300 George Street

                  • New Haven, CT 06511

                  • USA.Map

                  • Phone: +1 203 724-6000

                  • Fax: +1 203 624-7003

                  • achillion.com

                  Incorporated

                  1998

                  Employees

                  62

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: